New Age Alpha Advisors LLC Takes Position in DexCom, Inc. (NASDAQ:DXCM)

New Age Alpha Advisors LLC purchased a new position in shares of DexCom, Inc. (NASDAQ:DXCM) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 189,047 shares of the medical device company’s stock, valued at approximately $14,702,000. DexCom comprises approximately 0.6% of New Age Alpha Advisors LLC’s holdings, making the stock its 25th biggest holding.

Other institutional investors have also added to or reduced their stakes in the company. Versant Capital Management Inc bought a new position in DexCom during the fourth quarter worth about $25,000. Private Trust Co. NA increased its holdings in shares of DexCom by 266.3% in the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock valued at $26,000 after purchasing an additional 245 shares during the last quarter. TD Private Client Wealth LLC raised its holdings in DexCom by 62.8% in the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company’s stock valued at $34,000 after acquiring an additional 167 shares during the period. Larson Financial Group LLC increased its stake in shares of DexCom by 40.5% during the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock worth $37,000 after purchasing an additional 137 shares during the period. Finally, Heck Capital Advisors LLC acquired a new stake in shares of DexCom in the fourth quarter valued at approximately $38,000. 97.75% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on DXCM shares. Canaccord Genuity Group upped their price objective on DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a research note on Friday, February 14th. Baird R W raised DexCom from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 16th. Morgan Stanley raised their target price on DexCom from $75.00 to $82.00 and gave the company an “equal weight” rating in a research report on Friday, February 14th. Wells Fargo & Company restated an “overweight” rating on shares of DexCom in a research note on Saturday, March 8th. Finally, Cfra Research raised DexCom to a “hold” rating in a report on Friday, March 21st. Five investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $99.82.

Insider Activity at DexCom

In other news, COO Jacob Steven Leach sold 14,076 shares of the stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $990,668.88. Following the transaction, the chief operating officer now owns 313,497 shares of the company’s stock, valued at $22,063,918.86. This represents a 4.30 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Jereme M. Sylvain sold 2,090 shares of the company’s stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $181,641.90. Following the transaction, the executive vice president now directly owns 83,526 shares of the company’s stock, valued at $7,259,244.66. The trade was a 2.44 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 105,009 shares of company stock valued at $8,044,178 over the last 90 days. Insiders own 0.30% of the company’s stock.

DexCom Trading Down 3.7 %

DexCom stock opened at $69.47 on Friday. The firm has a 50-day moving average of $82.65 and a 200-day moving average of $77.02. DexCom, Inc. has a one year low of $62.34 and a one year high of $141.99. The company has a market cap of $27.15 billion, a price-to-earnings ratio of 48.58, a P/E/G ratio of 2.30 and a beta of 1.28. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. On average, equities analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.